Long-term monitoring should be planned to adjust the therapeutic doses according to the prolactin level, to detect complications related to the increase in tumor size or pituitary apoplexy, and to better understand the problems induced by estrogens in case of pregnancy or contraception. This evidence concerns the gene PRL and pituitary apoplexy.